Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 2, 2026

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

New pathways for evaluating potential acute stroke therapies.

Marc Fisher1, Kenneth Cheung, George Howard

  • 1Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA. fisherm@ummhc.org

International Journal of Stroke : Official Journal of the International Stroke Society
|August 19, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concurrent Metastatic Clear Cell Renal Cell Carcinoma and Chronic Lymphocytic Leukemia Within the Same Lymph Node: A Case Report and Review of Dual Malignancy Management.

Cureus·2025
Same author

Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHA<sub>2</sub>DS<sub>2</sub>-VASc-Biomarkers model.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Circulating biomarkers and ischemic stroke risk in adults with atrial fibrillation taking anticoagulation: the Reasons for Geographic And Racial Differences in Stroke study.

Journal of thrombosis and haemostasis : JTH·2025
Same author

MRI Findings of Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial.

AJNR. American journal of neuroradiology·2025
Same author

A model for the cognitive assessment of physicians.

Frontiers in public health·2025
Same author

The American Association of Cardiovascular and Pulmonary Rehabilitation National Pulmonary Rehabilitation Registry: Design and Participant Characteristics.

Journal of cardiopulmonary rehabilitation and prevention·2025

Developing new acute ischemic stroke treatments requires robust evidence. Combining large clinical trials with imaging biomarker data from phase IIB studies can support FDA approval for novel neuroprotective drugs.

Area of Science:

  • Neurology
  • Pharmacology
  • Medical Imaging

Background:

  • Current pharmacological treatments for acute ischemic stroke are limited, with only tissue plasminogen activator approved within a narrow time window.
  • Numerous neuroprotective drugs and thrombolytics have failed to gain regulatory approval due to insufficient evidence of efficacy and safety.

Purpose of the Study:

  • To propose an optimized development paradigm for novel acute ischemic stroke therapies.
  • To leverage the FDA Modernization Act of 1997 for drug approval pathways.
  • To integrate clinical trial data with imaging biomarker evidence for enhanced drug evaluation.

Main Methods:

  • Utilizing phase IIB trials to demonstrate treatment effects on imaging biomarkers like MRI or CT assessments of ischemic lesion growth.

Related Experiment Videos

Last Updated: Jul 2, 2026

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

  • Employing statistical approaches, such as 'pick the winner' strategies with interim assessments, to optimize phase IIB study design and reduce sample size.
  • Coupling a large phase III clinical trial with supportive phase IIB imaging data for regulatory submission.

    • Main Results:

    • Optimized statistical designs for imaging-based phase IIB studies can enhance efficiency and reduce sample size requirements.
    • Demonstrating a significant treatment effect on imaging biomarkers provides crucial supportive evidence for new drug applications.
    • This approach aims to strengthen the evidence base for novel acute ischemic stroke therapies.

    Conclusions:

    • A combined strategy of large phase III clinical trials and supportive phase IIB imaging biomarker data can facilitate FDA approval for new acute ischemic stroke drugs.
    • This paradigm offers a more efficient pathway for developing and approving effective neuroprotective therapies.
    • Successful demonstration of treatment effect on imaging biomarkers can bolster the case for clinical efficacy in subsequent phase III trials.